anti-NKG2D/anti-CD20 bispecific NK-cell engager (Christian-Albrechts-University Kiel/Genmab)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Nameanti-NKG2D/anti-CD20 bispecific NK-cell engager (Christian-Albrechts-University Kiel/Genmab)

Drug Alias NameMICA:CD20ULBP2:CD20

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Recombinant protein > Fusion protein

Mechanisms of ActionB-lymphocyte antigen CD20 modulatorsNKG2-D type II integral membrane protein agonists

TargetsB-lymphocyte antigen CD20NKG2-D type II integral membrane protein

Therapy Area/IndicationsLymphoma, B-Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryDenmarkGermany

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesChristian-Albrechts-University of Kiel

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesGenmab A/S Christian-Albrechts-University of Kiel

Active IndicationsN/A

Inactive IndicationsLymphoma, B-Cell

Other Information

ATC CodeN/A